The good news is that 10 of 11 are still using PRO 140 indicating it worked for them. This is clearly what the company was trying to communicate and it is also what everyone expected - that PRO 140 works. Additionally, the trial is now complete, which removes some uncertainty following the last PR which made it unclear when the trial would actually end.
The bad news is the 10/17 FDA meeting is sufficiently far away to complicate the chance of raising money to keep the company going. I have to assume they will find a way to financially get to 10/17 somehow as the stakes are just too high not to do so. But the company may not be meeting payroll in September.
The weird aspect of this is the apparent fact that either the trial was allowed to proceed without a well-defined protocol or the company is trying to change the agreed upon protocol with regard to analyzing the primary endpoint. It would have been appropriate for the company to explain this need for an FDA meeting before being able to produce the analysis of the primary endpoint. You will note the time frame for that meeting went from "coming weeks" to 10/17. I suspect we all hoped it would have been in late August or early September when we heard the "coming weeks" description. It does not seem like the FDA is in a rush to get this meeting on the agenda, but they are always moving slower than investors prefer.
Also, if a PR is not unambiguously good news, it likely hiding some bad news. Can some of the CYDY bulls offer up a good explanation for the need to meet with the FDA rather than just report out the results. With almost all patients completing the trial so far staying on PRO 140, what could possibly be the reason for not just analyzing and publishing the primary endpoint results? Then again, maybe they will do that and the meeting with the FDA is about other aspects of the data analysis, but you would think they would tell us that if it was the plan.
